Clin2
NCT07443228Likely a fitNot yet recruiting

A study of a new drug to boost immune cells in people with HIV

HIV

Treatments studied

Part of Infections clinical trials.

This trial tests a new drug called JL18008 (a man-made form of Interleukin-7) to see if it can help increase CD4 immune cells in people with HIV who are on effective antiretroviral therapy but have persistently low CD4 counts (between 100 and 350). It aims to improve immune function.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
52 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old.
  • You have been on stable HIV treatment (no changes) for at least 3 months and for at least 3 years overall.
  • Your viral load (amount of HIV in blood) has been very low or undetectable for at least 30 months.
  • Your CD4 cell count has been between 100 and 350 for at least a year, measured at least twice.
  • You have no autoimmune diseases (like lupus, psoriasis) or other serious health conditions listed.
  • You agree to use effective birth control during and for 3 months after the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07145164Enrolling by invitation· Phase 2
IL-15 to boost HIV control after pausing daily meds

This study tests whether giving a small protein called IL-15 can help your immune system keep HIV under control after pausing your daily HIV medications. You will stop your meds for a short time under careful monitoring, and the hope is that your body might learn to fight HIV without daily pills.

San Francisco, California
NCT07569029Recruiting· Phase 1
HIV vaccine with treatment break to boost immune response

This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.

Birmingham, Alabama
NCT07433387Recruiting· Phase 1/Phase 2
Study of a new HIV drug for people not on treatment

This trial tests a new injectable treatment called LP-98 for people with HIV who have never taken HIV medications before. It aims to see if the drug is safe and can help lower the virus in your body.

Tianjin, Tianjin Municipality
NCT07390955Recruiting· Phase 1
Safety study of three anti-HIV antibodies in healthy adults

This study is testing three experimental antibodies (ePGT121v1-LS, PGDM1400LS, and VRC07-523LS) that may help prevent HIV. It’s looking at their safety and how long they stay in the body. Healthy volunteers without HIV can join.

Birmingham, Alabama
NCT07054931Recruiting· Phase 2
Combination HIV vaccine and antibody therapy study

This trial tests a combination of an HIV vaccine and a new antibody treatment (GS-2872) to see if it can help control HIV without daily pills. It is for people with well-controlled HIV who are looking for ways to reduce their dependence on antiretroviral therapy.

London
NCT07579741Recruiting· Phase 1/Phase 2
Testing JL18008 for HIV Patients Not Recovering Immune Cells

This study tests an experimental drug called JL18008 in people with HIV who have been on stable HIV medications for years but whose immune systems (CD4 cells) haven't recovered as expected. The drug may help boost immune function in these patients.

Beijing, Beijing Municipality

Hear when a new HIV trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.